Company Overview and News
Blackham Resources Ltd (ASX:BLK) has entered into a binding term sheet with A-Cap Resources Ltd (ASX:ACB) to farm-out a 75% joint venture interest in the nickel, cobalt and associated metals of the Wiluna Cobalt Nickel (Wilconi) Project in WA.
BKHRF BLK ACB
RIU Resources Investor Roadshow in Sydney and Melbourne this week has drawn up to 600 investors eager to pick up clues from 21 presenting junior resources companies amidst a mood of increasing optimism in the industry.
CZN BKHRF BLK ATC
Blackham Resources Ltd (ASX:BLK) has executed an agreement with an entity managed by The Lind Partners for an investment of up to $23 million in total capital.
Blackham Resources Ltd’s (ASX:BLK) resource extension drilling around the Golden Age North pit indicates strong potential for high grade, free-milling ore at the Matilda-Wiluna gold operation in Western Australia.
Blackham Resources Ltd (ASX:BLK) has appointed chief financial officer Anthony Rechichi to the role of company secretary, following the resignation of Mike Robbins.
Blackham Resources Ltd (ASX:BLK) has revealed an upgraded resource of 96 million tonnes at 2.2 g/t gold for 6.7 million ounces of gold at its Matilda-Wiluna Operation in Western Australia.
Blackham Resources Ltd’s (ASX:BLK) drilling has identified high-grade extensions to the free-milling Williamson deposit at the Lake Way prospect, part of its Wiluna Gold Operation in Western Australia.
Blackham Resources Ltd (ASX:BLK) has appointed Geoff Jones as a non-executive director as it prepares for the next phase of its evolution as a gold producer.
RSG BKHRF RMGGY RMGGF BLK GNG
Blackham Resources Ltd (ASX:BLK) is set to benefit from the positive results of a scoping study evaluating the development of a potash demonstration plant at Lake Way, near its gold operations.
BKHRF SO4 SO4 WHELF BLK
Northern Star Resources has reported above-guidance gold production for the year to June, with plans to expand output beyond 600,000 ounces in 2019, while Blackham Resources posted improved results for the half-year to June.
BKHRF NST BLK NHRNY NESRF
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET